{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:47:25Z","timestamp":1782384445907,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"BeOne Medicines Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40487-026-00425-y","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:11:48Z","timestamp":1772892708000},"page":"639-654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase\u00a0Inhibitor Monotherapies in the Treatment of B\u00a0Cell Lymphomas"],"prefix":"10.1007","volume":"14","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priccila","family":"Zuchinali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Fahrbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Sadic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Mohseninejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"issue":"10438","key":"425_CR1","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","volume":"403","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt E, Salles G, Campo E, Dreyling M. B-cell non-Hodgkin lymphomas. Lancet. 2024;403(10438):1791\u2013807.","journal-title":"Lancet"},{"key":"425_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042208","author":"A Fares","year":"2024","unstructured":"Fares A, Carracedo Uribe C, Martinez D, Rehman T, Silva Rondon C, Sandoval-Sus J. Bruton\u2019s tyrosine kinase inhibitors: recent updates. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25042208.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"425_CR3","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"425_CR4","unstructured":"AstraZeneca. CALQUENCE\u00ae (alacabrutinib) prescibing information. 2025."},{"key":"425_CR5","unstructured":"BeOne Medicines USA I. BRUKINSA\u00ae (zanubrutinib) prescibing information. 2025."},{"key":"425_CR6","unstructured":"Janssen Biotech I. IMBRUVICA\u00ae (ibrutinib) prescibing information. 2024."},{"issue":"1","key":"425_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01353-w","volume":"15","author":"A Alu","year":"2022","unstructured":"Alu A, Lei H, Han X, Wei Y, Wei X. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. J Hematol Oncol. 2022;15(1):138.","journal-title":"J Hematol Oncol"},{"key":"425_CR8","first-page":"108","volume":"3","author":"WG Wierda","year":"2025","unstructured":"Wierda WG, Brown J, Abramson JS, et al. Chronic lymphocytic leukemia\/small lymphocytic lymphoma, Version 3.2025, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2025;3:108.","journal-title":"J Natl Compr Canc Netw"},{"key":"425_CR9","doi-asserted-by":"publisher","unstructured":"Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN Guidelines\u00ae Insights: B-cell lymphomas Version 3.2025. J Natl Compr Canc Netw. 2025:23:e250048. https:\/\/doi.org\/10.6004\/jnccn.2025.0048.","DOI":"10.6004\/jnccn.2025.0048"},{"issue":"31","key":"425_CR10","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase\u00a0III trial. J Clin Oncol. 2021;39(31):3441\u201352.","journal-title":"J Clin Oncol"},{"issue":"33","key":"425_CR11","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1200\/JCO.22.02830","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Opat S, D\u2019Sa S, et al. Zanubrutinib versus ibrutinib in symptomatic Waldenstrom macroglobulinemia: final analysis from the randomized phase\u00a0III ASPEN study. J Clin Oncol. 2023;41(33):5099\u2013106.","journal-title":"J Clin Oncol"},{"key":"425_CR12","unstructured":"Ferrant E, Brown JR, Eichhorst B, et al. Extended follow-up of ALPINE randomized phase\u00a03 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R\/R CLL\/SLL). Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019H\u00e9matologie; March 27\u201329, 2024; Paris, France2024."},{"issue":"1","key":"425_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/pst.2340","volume":"23","author":"HJ Weber","year":"2024","unstructured":"Weber HJ, Corson S, Li J, et al. Duration of and time to response in oncology clinical trials from the perspective of the estimand framework. Pharm Stat. 2024;23(1):91\u2013106.","journal-title":"Pharm Stat"},{"key":"425_CR14","unstructured":"Food and Drug Administration (FDA). Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry. 2018."},{"issue":"1","key":"425_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-024-00038-2","volume":"60","author":"J Kim","year":"2025","unstructured":"Kim J, Cho J, Lim JH, Lee MH. Relative efficacy of systemic treatments for patients with relapsed\/refractory chronic lymphocytic leukemia: a network meta-analysis according to 17p deletion\/TP53 mutations. Blood Res. 2025;60(1):1.","journal-title":"Blood Res"},{"issue":"11","key":"425_CR16","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1182\/bloodadvances.2023012142","volume":"8","author":"AS Kittai","year":"2024","unstructured":"Kittai AS, Allan JN, James D, et al. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Adv. 2024;8(11):2861\u20139.","journal-title":"Blood Adv"},{"key":"425_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241263710","volume":"16","author":"M Monica","year":"2024","unstructured":"Monica M, Reczek M, Kawalec P. Network meta-analysis of novel targeted therapies for relapsed\/refractory chronic lymphocytic leukemia. Ther Adv Med Oncol. 2024;16:17588359241263710.","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"425_CR18","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1182\/bloodadvances.2024014523","volume":"9","author":"M Shadman","year":"2025","unstructured":"Shadman M, Brown JR, Mohseninejad L, et al. Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed\/refractory CLL: a network meta-analysis. Blood Adv. 2025;9(12):2863\u201370.","journal-title":"Blood Adv"},{"issue":"2","key":"425_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1080\/10428194.2024.2416577","volume":"66","author":"C Thieblemont","year":"2025","unstructured":"Thieblemont C, Wahlin BE, Mohseninejad L, et al. Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed\/refractory marginal zone lymphoma. Leuk Lymphoma. 2025;66(2):240\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"425_CR20","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00277-023-05486-x","volume":"103","author":"S Yin","year":"2024","unstructured":"Yin S, Zheng X, Zhang W, et al. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia\/small lymphocytic lymphoma: a systematic review and meta-analysis. Ann Hematol. 2024;103(7):2231\u201344.","journal-title":"Ann Hematol"},{"key":"425_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251340554","volume":"17","author":"M Shadman","year":"2025","unstructured":"Shadman M, Brown JR, Williams R, et al. Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R\/R CLL): a matching-adjusted indirect comparison (MAIC). Ther Adv Med Oncol. 2025;17:17588359251340554.","journal-title":"Ther Adv Med Oncol"},{"key":"425_CR22","unstructured":"Deeks JJ, Higgins J, Altman DG, McKenzie JE, Veroniki AA. Chapter 10: Analysing data and undertaking meta-analyses [last updated November 2024]. Cochrane Handbook for Systematic Reviews of Interventions version 65: Cochrane; 2024."},{"issue":"11","key":"425_CR23","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440\u201350.","journal-title":"Blood Adv"},{"issue":"25","key":"425_CR24","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337.","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"425_CR25","doi-asserted-by":"publisher","first-page":"7510","DOI":"10.1200\/JCO.2017.35.15_suppl.7510","volume":"35","author":"JC Byrd","year":"2017","unstructured":"Byrd JC, Hillmen P, O\u2019Brien SM, et al. Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): up to four years follow-up of the resonate study. J Clin Oncol. 2017;35(15_suppl):7510.","journal-title":"J Clin Oncol"},{"issue":"2","key":"425_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase\u00a03 trial. Lancet Oncol. 2017;18(2):241\u201350.","journal-title":"Lancet Oncol"},{"issue":"25","key":"425_CR27","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"Ghia P, Pluta A, Wach M, et al. ASCEND: phase\u00a0III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849\u201361.","journal-title":"J Clin Oncol"},{"key":"425_CR28","doi-asserted-by":"crossref","unstructured":"Munir T, Shadman M, Robak T, et al. P639: Zanubrutinib (Zanu) vs bendamustine + rituximab (Br) in patients (Pts) with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma (Cll\/Sll): extended follow-up of the sequoia study. HemaSphere. 2023;7(S3):e15364af.","DOI":"10.1097\/01.HS9.0000969460.15364.af"},{"issue":"22","key":"425_CR29","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","volume":"4","author":"A Noy","year":"2020","unstructured":"Noy A, de Vos S, Coleman M,  et al. Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv. 2020;4(22):5773\u201384.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"425_CR30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood-2022-163371","volume":"140","author":"S Opat","year":"2022","unstructured":"Opat S, Tedeschi A, Hu B, et al. Long-term efficacy and safety of zanubrutinib in patients with relapsed\/refractory (R\/R) marginal zone lymphoma (MZL): final analysis of the Magnolia (BGB-3111-214) trial. Blood. 2022;140(Supplement 1):573\u20136.","journal-title":"Blood"},{"issue":"23","key":"425_CR31","doi-asserted-by":"publisher","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","volume":"27","author":"S Opat","year":"2021","unstructured":"Opat S, Tedeschi A, Linton K, et al. The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma. Clin Cancer Res. 2021;27(23):6323\u201332.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"425_CR32","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","volume":"7","author":"RG Owen","year":"2020","unstructured":"Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase\u00a02 study. Lancet Haematol. 2020;7(2):e112\u201321.","journal-title":"Lancet Haematol"},{"issue":"11","key":"425_CR33","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/bloodadvances.2021006083","volume":"6","author":"T Phillips","year":"2022","unstructured":"Phillips T, Chan H, Tam CS, et al. Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2022;6(11):3472\u20139.","journal-title":"Blood Adv"},{"issue":"5","key":"425_CR34","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","volume":"104","author":"S Rule","year":"2019","unstructured":"Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104(5):e211\u20134.","journal-title":"Haematologica"},{"issue":"7","key":"425_CR35","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO-24-02265","volume":"43","author":"M Shadman","year":"2025","unstructured":"Shadman M, Munir T, Robak T, et al. Zanubrutinib versus bendamustine and rituximab in patients with treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA. J Clin Oncol. 2025;43(7):780\u20137.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"425_CR36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood-2023-174750","volume":"142","author":"JP Sharman","year":"2023","unstructured":"Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib \u00b1 obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of elevate-TN. Blood. 2023;142(Supplement 1):636.","journal-title":"Blood"},{"issue":"5","key":"425_CR37","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/10428194.2024.2310141","volume":"65","author":"Y Song","year":"2024","unstructured":"Song Y, Li J, Zhou K, et al. Phase\u00a01\/2 multicenter trial of acalabrutinib in Chinese patients with relapsed\/refractory mantle cell lymphoma. Leuk Lymphoma. 2024;65(5):647\u201352.","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"425_CR38","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","volume":"26","author":"Y Song","year":"2020","unstructured":"Song Y, Zhou K, Zou D, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton\u2019s tyrosine kinase. Clin Cancer Res. 2020;26(16):4216\u201324.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"425_CR39","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.2021014162","volume":"139","author":"Y Song","year":"2022","unstructured":"Song Y, Zhou K, Zou D, et al. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase\u00a02 study. Blood. 2022;139(21):3148\u201358.","journal-title":"Blood"},{"issue":"1","key":"425_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjh.18368","volume":"199","author":"P Strati","year":"2022","unstructured":"Strati P, Coleman M, Champion R, et al. A phase\u00a02, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. Br J Haematol. 2022;199(1):76\u201385.","journal-title":"Br J Haematol"},{"issue":"8","key":"425_CR41","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase\u00a03 trial. Lancet Oncol. 2022;23(8):1031\u201343.","journal-title":"Lancet Oncol"},{"issue":"18","key":"425_CR42","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood.2020006449","volume":"136","author":"J Trotman","year":"2020","unstructured":"Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3\u00a0years of follow-up. Blood. 2020;136(18):2027\u201337.","journal-title":"Blood"},{"issue":"10121","key":"425_CR43","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase\u00a02 trial. Lancet. 2018;391(10121):659\u201367.","journal-title":"Lancet"},{"issue":"26","key":"425_CR44","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517\u201328.","journal-title":"N Engl J Med"},{"issue":"18","key":"425_CR45","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam CS, Opat S, D\u2019Sa S, et al. A randomized phase\u00a03 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038\u201350.","journal-title":"Blood"},{"issue":"47","key":"425_CR46","first-page":"803","volume":"112","author":"C Kiefer","year":"2015","unstructured":"Kiefer C, Sturtz S, Bender R. Indirect comparisons and network meta-analyses. Dtsch Arztebl Int. 2015;112(47):803\u20138.","journal-title":"Dtsch Arztebl Int"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00425-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00425-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00425-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:53:25Z","timestamp":1782381205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00425-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["425"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00425-y","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pier Luigi Zinzani is affiliated with the University of Bologna and IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; consultant with AstraZeneca, Novartis, MSD, and BeOne Medicines; and attending advisory boards for AstraZeneca, BeOne Medicines, BMS, Eli Lilly, Generon, Incyte, Janssen-Cilag, Kyowa Kirin, MSD Pharma, Novartis, Roche, Sandoz, Secura Bi, SOBI, Takeda, Kite Gilead, Reccordata, and ADS Therapy. Binod Neupane, Priccila Zuchinali, Kyle Fahrbach, and Heather Burnett are employed by Evidera, which has received research funding from BeOne Medicines. Rhys Williams, Mei Xue, Dennis Sadic, Leyla Mohseninejad, Keri Yang are employed by and hold stock options for BeOne Medicines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}